EyePoint announced topline data from the LUGANO Phase 3 trial for DURAVYU in wet AMD. The primary endpoint was not achieved in the full dataset due to an asymmetric cohort of nine patients experiencing vision loss unrelated to wet AMD. However, an ad hoc analysis excluding this group showed non-inferiority versus aflibercept (p=0.0096). Key secondary endpoints were met, including a 42% reduction in treatment burden and superior supplement-free rates. The company plans to report LUCIA data in Q4 2026 and submit an NDA in H1 2027. EyePoint is a clinical-stage biopharmaceutical company developing therapeutics for retinal diseases.
